Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials

European urology oncology - Tập 3 - Trang 540-543 - 2020
Guru P. Sonpavde1, Gregory R. Pond2, Karim Fizazi3, Johann S. de Bono4, Ethan M. Basch5, Howard I. Scher6, Matthew R. Smith7
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2McMaster University, Hamilton, ON, Canada
3Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France
4Institute of Cancer Research and The Royal Marsden Hospital, London, UK
5University of North Carolina, Chapel Hill, NC, USA
6Memorial Sloan-Kettering Cancer Center, New York, NY, USA
7Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

Tài liệu tham khảo

Smith, 2016, Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1, J Clin Oncol, 34, 3005, 10.1200/JCO.2015.65.5597 Basch, 2015, Final analysis of COMET-2: cabozantinib versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer patients with moderate to severe pain who were previously treated with docetaxel and abiraterone and/or enzalutamide, J Clin Oncol, 33, 141, 10.1200/jco.2015.33.7_suppl.141 Smith, 2014, Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study, J Clin Oncol, 32, 3391, 10.1200/JCO.2013.54.5954 Smith, 2013, Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J Clin Oncol, 31, 412, 10.1200/JCO.2012.45.0494 Escudier, 2018, Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial, J Clin Oncol, 36, 765, 10.1200/JCO.2017.74.7352 Halabi, 2013, Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, 105, 1729, 10.1093/jnci/djt280 Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696 Chi, 2016, A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, 27, 454, 10.1093/annonc/mdv594 Goyal, 2017, A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma, Cancer, 123, 1979, 10.1002/cncr.30571 Klempner, 2017, Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases, J Thorac Oncol, 12, 152, 10.1016/j.jtho.2016.09.127
Thông tin
Thông tin xuất bản

European urology oncology

Tập 3

540-543

Thông tin tác giả